Parkinson’s Disease Drugs Market Introduction and Overview
According to SPER Market Research, the Global Parkinson’s Disease Drugs Market is estimated to reach USD 10.93 billion by 2032 with a CAGR of 6.5%.
The report includes an in-depth analysis of the global Parkinson’s Disease Drugs market, including market size and trends, Procedure mix, distribution channels, and supplier analysis. Parkinson's disease is a neurodegenerative disorder characterized by progressive loss of dopamine-producing cells in the brain, resulting in motor symptoms such as tremors, rigidity, and impaired balance, as well as non-motor symptoms.
- Increasing Prevalence of Parkinson's Disease: The growing global burden of Parkinson's disease, attributed to factors like aging populations and changing lifestyles, is driving the demand for effective drugs to manage the condition.
- Advancements in Research and Development: Ongoing research and development activities are leading to the discovery of novel therapeutic approaches, including disease-modifying treatments and innovative drug delivery systems. These advancements contribute to market growth by expanding the treatment options available.
Market Opportunities and Challenges
The global Parkinson's disease drugs market is propelled by various growth factors. These include the increasing prevalence of Parkinson's disease worldwide, advancements in research and development leading to new therapeutic approaches, rising healthcare expenditure enabling greater access to drugs, technological innovations improving disease management, and supportive government initiatives promoting research and providing incentives. These factors contribute to market growth by driving demand, expanding treatment options, enhancing outcomes, and fostering innovation. As a result, the global Parkinson's disease drugs market is expected to continue expanding.
However, the treatment of Parkinson's disease poses challenges due to the variable response to medications among individuals and the progressive nature of the disease. Ensuring access to affordable medications globally, especially in low-income regions, is a significant challenge. Additionally, developing disease-modifying therapies to target the underlying causes of Parkinson's is a major hurdle. Overcoming these challenges requires sustained investment in research, collaboration between stakeholders, and regulatory support to advance innovative therapies. Addressing these challenges will contribute to improved treatment outcomes and enhanced quality of life for individuals with Parkinson's disease.
-010362223082023.jpg)
Market Competitive Landscape
The global Parkinson’s Disease Drugs is characterized by high competition, with multiple players operating in the industry. The key players in the global Parkinson’s Disease Drugs market include Teva Pharmaceuticals, C.H., Amneal Pharmaceuticals, Inc., Intas Pharmaceuticals Limited, Square group, UCB, F.Hoffmann-La Roche Ltd., Pfizer Inc., Biogen Inc., Viatris Inc., Novartis AG, Orion Corporation, Gentech Healthcare, GlaxoSmithKline Plc, Torrent Group, Sun Pharmaceutical Industries, Boehringer Sohn Ko. KG, Merck & Co., Inc., Eli Lilly and Company, and AbbVie Inc., Others.
Scope of the Report:
| Report Metric | Details |
| Market size available for years | 2019-2032 |
| Base year considered | 2021 |
| Forecast period | 2022-2032 |
| Segments covered | By Age Group, By Drug Class, By Route of Administration
|
| Geographies covered | North America, Asia-Pacific, Latin America, Middle East & Africa and Europe
|
| Companies Covered | Teva Pharmaceuticals, C.H., Amneal Pharmaceuticals, Inc., Intas Pharmaceuticals Limited, Square group, UCB, F.Hoffmann-La Roche Ltd., Pfizer Inc., Biogen Inc., Viatris Inc., Novartis AG, Orion Corporation, Gentech Healthcare, GlaxoSmithKline Plc, Torrent Group, Sun Pharmaceutical Industries, Boehringer Sohn Ko. KG, Merck & Co., Inc., Eli Lilly and Company, and AbbVie Inc., Others
|
COVID-19 Impact on Global Parkinson’s Disease Drugs Market
The Covid-19 epidemic has had a tremendous influence on the market. The COVID-19 pandemic had little impact on the global market for Parkinson's disease medications. The epidemic has had a direct influence on Parkinson's medicine supply and demand; it has disrupted distribution networks; and it has had a financial impact on enterprises and financial markets. However, clinical trials have risen, and various studies have been undertaken to determine the impact of Covid-19 on Parkinson's disease patients.
Key Target Audience
- Healthcare Institutions
- Healthcare Professionals
- Patients and Caregivers
- Public and Private Healthcare Providers
- Research Institutions and Academia
- Others
Our in-depth analysis of the Parkinson’s Disease Drugs Market includes the following segments:
|
By Age Group:
|
50 or below 50
Above 50 years
|
|
By Drug Class:
|
Decarboxylase Inhibitors
Dopamine Agonists
COMT Inhibitors
MAO-B Inhibitors
Others
|
|
By Route of Administration:
|
Injectable
Oral
Transdermal
|
Key Topics Covered in the Report
- Global Parkinson’s Disease Drugs Market Size (FY’2022-FY’2032)
- Overview of Global Parkinson’s Disease Drugs Market
- Segmentation of Global Parkinson’s Disease Drugs Market By Age Group (Above 50, Below 50, 50)
- Segmentation of Global Parkinson’s Disease Drugs Market By Drug Class (Dopamine Agonists, MAO-B Inhibitors, COMT Inhibitors, Decarboxylase inhibitors, Others)
- Segmentation of Global Parkinson’s Disease Drugs Market By Route of Administration (Injectable, Oral, Transdermal)
- Statistical Snap of Global Parkinson’s Disease Drugs Market
- Expansion Analysis of Global Parkinson’s Disease Drugs Market
- Problems and Obstacles in Global Parkinson’s Disease Drugs Market
- Competitive Landscape in the Global Parkinson’s Disease Drugs Market
- Impact of COVID-19 and Demonetization on Global Parkinson’s Disease Drugs Market
- Details on Current Investment in Global Parkinson’s Disease Drugs Market
- Competitive Analysis of Global Parkinson’s Disease Drugs Market
- Prominent Players in the Global Parkinson’s Disease Drugs Market
- SWOT Analysis of Global Parkinson’s Disease Drugs Market
- Global Parkinson’s Disease Drugs Market Future Outlook and Projections (FY’2022-FY’2032)
- Recommendations from Analyst
1. Introduction
1.1. Scope of the report
1.2. Market segment analysis
2. Research Methodology
2.1 Research data source
2.1.1 Secondary data
2.1.2 Primary data
2.1.3 SPER’s internal database
2.1.4 Premium insight from KOL’s
2.2 Market size estimation
2.2.1 Top-down and Bottom-up approach
2.3 Data triangulation
3. Executive Summary
4. Market Dynamics
4.1. Driver, Restraint, Opportunity and Challenges analysis
4.1.1 Drivers
4.1.2 Restraints
4.1.3 Opportunities
4.1.4 Challenges
4.2. COVID-19 Impacts of the Global Parkinson’s Disease Drugs Market
5. Market variables and outlook
5.1. SWOT analysis
5.1.1 Strengths
5.1.2 Weaknesses
5.1.3 Opportunities
5.1.4 Threats
5.2. PESTEL analysis
5.2.1 Political landscape
5.2.2 Economic landscape
5.2.3 Social landscape
5.2.4 Technological landscape
5.2.5 Environmental landscape
5.2.6 Legal landscape
5.3. PORTER’S five forces analysis
5.3.1 Bargaining power of suppliers
5.3.2 Bargaining power of Buyers
5.3.3 Threat of Substitute
5.3.4 Threat of new entrant
5.3.5 Competitive rivalry
5.4. Heat map analysis
6. Global Parkinson’s Disease Drugs Market, By Age Group, 2019-2032 (USD Million)
6.1. 50 or below 50
6.1.1. Key market trends, growth factors and opportunities
6.1.2. Market size and forecast
6.1.3. Market analysis by Region
6.2. Above 50 years
6.2.1. Key market trends, growth factors and opportunities
6.2.2. Market size and forecast
6.2.3. Market analysis by Region
7. Global Parkinson’s Disease Drugs Market, By Drug Class, 2019-2032 (USD Million)
7.1. Decarboxylase Inhibitors
7.1.1. Key market trends, growth factors and opportunities
7.1.2. Market size and forecast
7.1.3. Market analysis by Region
7.1.4. Decarboxylase Inhibitors Parkinson's Disease Drugs Market by Distribution Channel
7.1.4.1 Hospital Pharmacies Market size and forecast, by region
7.1.4.2 Drug stores and Retail Pharmacies Market size and forecast, by region
7.1.4.3 Online Providers Market size and forecast, by region
7.2. Dopamine Agonists
7.2.1. Key market trends, growth factors and opportunities
7.2.2. Market size and forecast
7.2.3. Market analysis by Region
7.3. COMT Inhibitors
7.3.1. Key market trends, growth factors and opportunities
7.3.2. Market size and forecast
7.3.3. Market analysis by Region
7.4. MAO-B Inhibitors
7.4.1. Key market trends, growth factors and opportunities
7.4.2. Market size and forecast
7.4.3. Market analysis by Region
7.5. Others
7.5.1. Key market trends, growth factors and opportunities
7.5.2. Market size and forecast
7.5.3. Market analysis by Region
8. Global Parkinson’s Disease Drugs Market, By Route of Administration, 2019-2032 (USD Million)
8.1. Injectable
8.1.1. Key market trends, growth factors and opportunities
8.1.2. Market size and forecast
8.1.3. Market analysis by Region
8.2. Oral
8.2.1. Key market trends, growth factors and opportunities
8.2.2. Market size and forecast
8.2.3. Market analysis by Region
8.3. Transdermal
8.3.1. Key market trends, growth factors and opportunities
8.3.2. Market size and forecast
8.3.3. Market analysis by Region
9. Global Parkinson’s Disease Drugs Market, By Region, 2019-2032 (USD Million)
9.1. North America
9.1.1. United States
9.1.2. Canada
9.1.3. Mexico
9.2. Europe
9.2.1. Germany
9.2.2. United Kingdom
9.2.3. France
9.2.4. Italy
9.2.5. Spain
9.2.6. Rest of Europe
9.3. Asia-Pacific
9.3.1. China
9.3.2. Japan
9.3.3. India
9.3.4. Australia
9.3.5. South Korea
9.3.6. Rest of Asia-Pacific
9.4. South America
9.4.1. Brazil
9.4.2. Argentina
9.4.3. Rest of South America
9.5. Middle East & Africa
9.5.1. Kingdom of Saudi Arabia
9.5.2. United Arab Emirates
9.5.3. Rest of Middle East & Africa
10. Company Profiles
10.1. AbbVie Inc.
10.1.1. Company details
10.1.2. Financial outlook
10.1.3. Product summary
10.1.4. Recent developments
10.2. Amneal Pharmaceuticals, Inc.
10.2.1. Company details
10.2.2. Financial outlook
10.2.3. Product summary
10.2.4. Recent developments
10.3. Biogen Inc., C.H.
10.3.1. Company details
10.3.2. Financial outlook
10.3.3. Product summary
10.3.4. Recent developments
10.4. Boehringer Sohn Ko. KG
10.4.1. Company details
10.4.2. Financial outlook
10.4.3. Product summary
10.4.4. Recent developments
10.5. Eli Lilly and Company
10.5.1. Company details
10.5.2. Financial outlook
10.5.3. Product summary
10.5.4 Recent developments
10.6. F.Hoffmann-La Roche Ltd.
10.6.1. Company details
10.6.2. Financial outlook
10.6.3. Product summary
10.6.4. Recent developments
10.7. Gentech Healthcare
10.7.1. Company details
10.7.2. Financial outlook
10.7.3. Product summary
10.7.4. Recent developments
10.8. GlaxoSmithKline Plc
10.8.1. Company details
10.8.2. Financial outlook
10.8.3. Product summary
10.8.4. Recent developments
10.9. Intas Pharmaceuticals Limited
10.9.1. Company details
10.9.2. Financial outlook
10.9.3. Product summary
10.9.4. Recent developments
10.10. Merck & Co., Inc.
10.10.1. Company details
10.10.2. Financial outlook
10.10.3. Product summary
10.10.4. Recent developments
10.11 Novartis AG
10.11.1. Company details
10.11.2. Financial outlook
10.11.3. Product summary
10.11.4. Recent developments
10.12. Orion Corporation
10.12.1. Company details
10.12.2. Financial outlook
10.12.3. Product summary
10.12.4. Recent developments
10.13. Pfizer Inc.
10.13.1. Company details
10.13.2. Financial outlook
10.13.3. Product summary
10.13.4. Recent developments
10.14. Square group
10.14.1. Company detail
10.14.2. Financial outlook
10.14.3. Product summary
10.14.4. Recent developments
10.15. Sun Pharmaceutical Industries
10.15.1. Company details
10.15.2. Financial outlook
10.15.3. Product summary
10.15.4. Recent developments
10.16. Teva Pharmaceuticals
10.16.1. Company details
10.16.2. Financial outlook
10.16.3. Product summary
10.16.4. Recent development
10.17. Torrent Group
10.17.1. Company details
10.17.2. Financial outlook
10.17.3. Product summary
10.17.4. Recent development
10.18. UCB
10.18.1. Company details
10.18.2. Financial outlook
10.18.3. Product summary
10.18.4. Recent development
10.19. Viatris Inc.
10.19.1. Company details
10.19.2. Financial outlook
10.19.3. Product summary
10.19.4. Recent development